Literature DB >> 2403378

Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam.

P J McNamara1, V Trueb, K Stoeckel.   

Abstract

In vitro protein binding studies were conducted to examine the interaction between ceftriaxone (CEF), probenecid (PROB) and diazepam (DIAZ). The presence of PROB and DIAZ at concentrations equal to molar albumin concentration caused a decrease in CEF affinity from 3.7 x 10(4) M-1 (control) to 1.1 x 10(4) (PROB) and 2.6 x 10(4) (DIAZ) M-1, but not in binding capacity in pooled human plasma. PROB and DIAZ at five times the molar albumin concentration also caused a decrease in CEF affinity from 4.5 x 10(4) M-1 (control) to 0.45 x 10(4) (PROB) and 3.0 x 10(4) (DIAZ) M-1 in isolated human serum albumin. DIAZ and PROB displaced one another, confirming their common binding site (Site II, the benzodiazepine site) on serum albumin. By contrast, CEF was unable to displace either PROB or DIAZ from defatted albumin. In the presence of elevated free fatty acid concentrations (four times the albumin concentration), CEF decreased the binding of both drugs. CEF free fraction (fp) in isolated human serum albumin (CEF fp = 7.7%) was increased by drugs which bind to Site I: sulfisoxazole (CEF fp = 68.1%), warfarin (CEF fp = 56.0%) and furosemide (CEF fp = 55.0%). At ten times the molar concentration of albumin, CEF displaced both warfarin (warfarin fp from 0.99 to 2.20%) and phenytoin (phenytoin fp from 17.7 to 23.4%) from defatted albumin. CEF appeared to bind to Site I (the warfarin site) on human serum albumin, and was displaced by PROB and DIAZ via a mechanism which did not involve direct competition at a common binding site.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403378     DOI: 10.1016/0006-2952(90)90390-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen.

Authors:  E Tsivou; I Melakopoulos; A Kotsiou; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

3.  Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Authors:  Marija Djukic; Martin Munz; Fritz Sörgel; Ulrike Holzgrabe; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

4.  Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.

Authors:  Michael Schleibinger; Cathérine L Steinbach; Christoph Töpper; Alexander Kratzer; Uwe Liebchen; Frieder Kees; Bernd Salzberger; Martin G Kees
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

5.  Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal.

Authors:  Denis Garot; Renaud Respaud; Philippe Lanotte; Nicolas Simon; Emmanuelle Mercier; Stephan Ehrmann; Dominique Perrotin; Pierre-François Dequin; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 6.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases.

Authors:  Kazuma Ogawa; Takahiro Mukai; Keiichi Kawai; Norito Takamura; Hirofumi Hanaoka; Kazuyuki Hashimoto; Kazuhiro Shiba; Hirofumi Mori; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-16       Impact factor: 9.236

8.  The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults.

Authors:  Satofumi Iida; Haruki Kinoshita; Takehiko Kawanishi; Masahiro Hayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

9.  Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Ya-Kun Wang; Yue-E Wu; Dian-Ping You; Wei Zhao; Xue Li; Li-Yuan Tian; Muhammad Wasim Khan; Bo-Hao Tang; Hai-Yan Shi; Yi Zheng; Guo-Xiang Hao; John van den Anker
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin.

Authors:  Keishi Yamasaki; Saya Hyodo; Kazuaki Taguchi; Koji Nishi; Noriyuki Yamaotsu; Shuichi Hirono; Victor Tuan Giam Chuang; Hakaru Seo; Toru Maruyama; Masaki Otagiri
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.